CN Patent

CN1668623A — 一种拟多晶型hiv蛋白酶抑制剂

Assigned to Janssen R&D Ireland ULC · Expires 2005-09-14 · 21y expired

What this patent protects

本发明公开(3R，3aS，6aR)－六氢呋喃并[2，3－b]呋喃－3－基(1S，2R)－3－[[(4－氨基苯基)磺酰基](异丁基)氨基]－1－苄基－2－羟基丙基氨基甲酸酯的新颖的多晶型物及其生产方法。

USPTO Abstract

本发明公开(3R，3aS，6aR)－六氢呋喃并[2，3－b]呋喃－3－基(1S，2R)－3－[[(4－氨基苯基)磺酰基](异丁基)氨基]－1－苄基－2－羟基丙基氨基甲酸酯的新颖的多晶型物及其生产方法。

Drugs covered by this patent

Prezista (DARUNAVIR) · Janssen Prods

Patent Metadata

Patent number: CN1668623A
Jurisdiction: CN
Classification: —
Expires: 2005-09-14
Drug substance claim: No
Drug product claim: No
Assignee: Janssen R&D Ireland ULC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.